A new definition of obesity is dividing medicine. The underlying data says the division is mostly unnecessary.
The Lancet Commission on Clinical Obesity, a group of 58 commissioners from multiple countries and specialties, proposed in January 2025 that obesity be split into two categories: preclinical obesity, meaning excess body fat without current illness, and clinical obesity, meaning measurable organ damage that warrants treatment. Their goal was to target medical resources at people who needed them most, rather than diagnosing everyone with a high BMI as diseased.
A February 2026 validation study applied the new criteria to three population datasets. The finding that nobody in the debate seems to be talking about: 100 percent of people with a BMI of 30 or higher were confirmed as having obesity by at least one additional criterion, and roughly 80 percent already met the threshold for clinical obesity. The preclinical category, the supposedly healthy-at-risk group that sparked so much concern, turns out to be about one in five obese adults. The new definition sounds like a massive expansion of disease. The underlying data says most people were already in the disease bucket.
The commission's framework was endorsed by more than 75 international medical organizations, a striking level of agreement in a field that rarely gets it. The clinical definition carries real weight: people with clinical obesity had approximately three times the risk of cardiovascular disease and roughly eight times the risk of type 2 diabetes compared with people without obesity. Which bucket a patient lands in determines whether their treatment is covered.
The fight is really about insurance. The Obesity Medicine Association warned that fragmenting obesity into preclinical and clinical categories risks excluding people classified as preclinical from insurance coverage for essential medical weight management treatments, effectively delaying treatment until disease progresses. Francisco Lopez-Jimenez, a cardiologist at the Mayo Clinic, put it directly: we have to be careful that calling a condition preclinical does not lead to less treatment for those individuals.
Fatima Cody Stanford, an obesity researcher at Massachusetts General Hospital and Harvard Medical School, acknowledged the insurance problem but offered a different angle. Preclinical obesity will struggle, I think, in terms of coverage by insurers. But before, it was not even being acknowledged. The new category creates a paper trail that insurers can use to deny coverage, she is saying, but at least the condition is now on the record.
Francesco Rubino, a co-author of the commission's recommendations and a surgeon at King's College London, has a different frustration. He called for radical change, arguing that no country is rich enough to absorb the cost of inaccurate diagnosis when 1 billion people globally are classified as obese. But the commission's own data suggests the inaccuracy they were worried about runs in the other direction: most people with elevated BMI are not borderline cases. They are already sick.
No one planned for 75 percent of American adults to qualify. A Yale-led analysis found that more than 90 percent of adults over age 50 met criteria under the new definition. If every person with clinical obesity were guaranteed treatment, the new definition might be cause for celebration. Instead the argument is over who gets a bill.
Some evidence for intervention is genuine. A nine-month lifestyle intervention in the TULIP study lowered the rate of clinical obesity from 71 percent to 57 percent and prediabetes from 52 percent to 29 percent. But lifestyle interventions at scale require sustained access to nutritionists, coaches, and monitoring that most health plans do not cover for the preclinical group. The biology of obesity is yielding to better drugs, particularly the GLP-1 receptor agonist class. Supply is still constrained, costs are high, and insurance coverage outside diabetes and established cardiovascular disease is inconsistent.
There is a prior that haunts this debate. Katherine Flegal, an epidemiologist, noted that the current BMI categories were largely created in the 1990s under WHO auspices by a private group predominantly funded by pharmaceutical companies. The new definition aims to be more rigorous. Whether it creates a more equitable system for treatment or just a new administrative lever for denial is what ENDO 2026, the endocrine society's annual meeting in Chicago this June, will spend three days arguing.
The commission thought they were drawing a line between risk factors and disease. The data says most people with elevated BMI are already past that line.
